

BIOTECHNOLOGY LAW GROUP
PATENT, TRADEMARK & COPYRIGHT ATTORNEYS
527 N. Highway 101, Suite E

Telephone 858 350 9690

Facsimile 858 350-9691

RECEIVED
CENTRAL FAX CENTER

JUL 27 2007

Fax Transmission

To: Mail Stop M Correspondence
Company: United States Patent & Trademark Office
Fax #: 571-273-8300

From: Daniel M. Chambers
Date: July 27, 2007
Re: Docket # GTI-1370-DV

**You should receive 3 page(s) including this one.
If you do not receive all pages, please call 858 350 9690.**

Genetronics, Inc.: GTI-1370-DV

Matter: METHOD AND APPARATUS FOR REDUCING ELECTROPORATION-MEDIATED
MUSCLE REACTION AND PAIN RESPONSE

Dear Sir/Madam:

I respectfully submit via facsimile transmission the cover sheet and a letter to claim Large Entity status for the above-identified patent. Your prompt attention to implement this change is requested.
Thank you in advance for your assistance.

Should you have any questions, please do not hesitate to contact me.

Sincerely,

Daniel M. Chambers (Reg. No.: 34,561)
BioTechnology Law Group

This transmission contains information that is confidential and/or legally privileged. It is intended for use only by the person to whom it is directed. If you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the return of the original documents to us. If you do NOT receive all of the pages, please telephone us in the U.S.A. at 858 350 9690 or FAX us at 858 350-9691.

BIOTECHNOLOGY LAW GROUP

527 N. HIGHWAY 101, SUITE F
SOLANA BEACH, CA 92075-1173

DANIEL M. CHAMBERS, A. P. C.
TEL: (858) 350-9690 FAX: (858) 350-9691
EMAIL: dan@biotechnologylawgroup.com

July 27, 2007

Mail Stop M Correspondence
Director of the US Patent and Trademark Office
PO Box 1450
Alexandria, VA 22313-1450

RECEIVED
CENTRAL FAX CENTER

JUL 27 2007

Re: USA Application 10/115,230, Patent 6,800,484;
BLG Ref: GTI-1120-DV

Re: USA Application 09/090,471, Patent 6,027,488;
BLG Ref: GTI-1220-UT

Re: USA Application 09/307,216, Patent 6,347,247;
BLG Ref: GTI-1230-UT

Re: USA Application 10/339,708, Patent 7,171,264;
BLG Ref: GTI-1360-CP

Re: USA Application 10/215,963, Patent 7,054,685;
BLG Ref: GTI-1370-DV

Re: USA Application 07/929,103, Patent 5,273,525;
BLG Ref: GTI-1500-UT

Re: USA Application 09/176,136, Patent 6,150,148;
BLG Ref: GTI-1560-UT

Re: USA Application 08/729,007, Patent 5,704,908;
BLG Ref: GTI-1580-UT

Re: USA Application 09/874,468, Patent 6,748,265;
BLG Ref: GTI-1590-UT2

Re: USA Application 10/620,271, Patent 6,958,060;
BLG Ref: GTI-5000-CT3

Mail Stop M Correspondence
Director of the US Patent and Trademark Office
July 27, 2007
Page 2

RECEIVED
CENTRAL FAX CENTER
JUL 27 2007

Please note that the referenced patents qualify as a large entity. If you have any questions please do not hesitate to contact me.

Sincerely,



Daniel M. Chambers
Daniel M. Chambers, A.P.C.
BioTechnology Law Group

DMC:dg